The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant (Q37956385)

25 August 2017

The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant (English)

1 reference

25 August 2017

0 references

Siddhartha Jain

1

1 reference

PubMed ID

22085176

25 August 2017

Derek T O'Hagan

series ordinal

2

1 reference

PubMed ID

22085176

25 August 2017

Manmohan Singh

series ordinal

3

1 reference

25 August 2017

1 December 2011

1 reference

Expert Review of Vaccines

25 August 2017

1 reference

25 August 2017

10

1 reference

25 August 2017

12

1 reference

25 August 2017

1731-1742

1 reference

25 August 2017

New vaccine development

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Demographic impact of vaccination: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The path to a successful vaccine adjuvant--'the long and winding road'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Toll-like receptors: balancing host resistance with immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Vaccine technology: looking to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Mechanisms of stimulation of the immune response by aluminum adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Commercial challenges of protein drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Particulate delivery systems for biodefense subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Encapsulation of proteins in biodegradable polymeric microparticles using electrospray in the Taylor cone-jet mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Improved activity and stability of lysozyme at the water/CH2Cl2 interface: enzyme unfolding and aggregation and its prevention by polyols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Directed cell migration via chemoattractants released from degradable microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Protein instability in poly(lactic-co-glycolic acid) microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Stabilization of a model formalinized protein antigen encapsulated in poly(lactide-co-glycolide)-based microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Stabilization of tetanus toxoid encapsulated in PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Biodegradable polymers as non-viral carriers for plasmid DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Cationic microparticles are a potent delivery system for a HCV DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Microparticles for the delivery of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Cationic microparticles: A potent delivery system for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The history of vaccines and immunization: familiar patterns, new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Effect of c-Sterilization Process on PLGA Microspheres Loaded with Insulin-Like Growth Factor - I (IGF-I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Poly(I:C) coated PLGA microparticles induce dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Triggering TLR signaling in vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Recent advances in the discovery and delivery of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Combination adjuvants: the next generation of adjuvants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

21 January 2018

TLR based therapeutics

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Microparticles as vaccine adjuvants and delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Nanoparticles and microparticles as vaccine-delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Current major cancer targets for nanoparticle systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Pathogen recognition and development of particulate vaccines: does size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Particle size determines activation of the innate immune system in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

A comparison of anionic nanoparticles and microparticles as vaccine delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Towards designer microparticles: simultaneous control of anisotropy, shape, and size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The effect of particle design on cellular internalization pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Surfactant-free formulation of poly(lactic/glycolic) acid nanoparticles encapsulating functional polypeptide: a technical note

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

21 January 2018

ISCOMs and ISCOMATRIX.

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

Liposomes as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.126

21 January 2018

Identifiers

DOI

10.1586/ERV.11.126

1 reference

25 August 2017

1 reference

PubMed ID

22085176